Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue: +10.2%
EPS: +22.2%
Free cash flow: −4.83%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

69.74 1.03 +1.50%

Follow EXEL

Alert me

Market cap: $16.8B
P/E: 19.9×
Fwd P/E: 20.2×
Dividend yield: —
F-score: 7/9
Altman Z: 12.68
Beneish M: −2.61
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Exelixis, Inc. 10-Q filed May 5, 2026

Fiscal Q1 2026 · Period ended Apr 3, 2026 · Filed May 5, 2026 · accepted 4:11 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov